Interleukin 6 and complement serum level study in Parkinson's disease

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors

VESELÝ Branislav DUFEK Michal THON Vojtěch BROZMAN M. KIRALOVA S. HALASZOVA T. KORIŤÁKOVÁ Eva REKTOR Ivan

Year of publication 2018
Type Article in Periodical
Magazine / Source Journal of Neural Transmission
MU Faculty or unit

Central European Institute of Technology

Citation
Web https://link.springer.com/article/10.1007%2Fs00702-018-1857-5
Doi http://dx.doi.org/10.1007/s00702-018-1857-5
Keywords Complement; Interleukin 6; Parkinson's disease
Description The objective of this study is to assess whether elevation of serum inflammatory markers levels may indicate the progression of clinical impairment in Parkinson's disease (PD) patients. In 47 PD patients, the serum levels of the C3 and C4 part of the complement and Interleukin-6 (IL-6) were measured. The results at baseline and after 2 years were correlated with scales measuring memory, depression, motor symptoms, and quality of life. Patients with higher levels of C3 and C4 at baseline had decreased quality of life, verbal ability, and memory. Patients with higher IL-6 at baseline showed worse depression scores at 2 years. Patients with persistently higher levels of C3 and C4 at 2 years had worse quality of life and memory ability. Uncorrected p values are reported due to the exploratory nature of the study. The results indicate an impact of inflammation on non-motor signs and quality of life in PD. The increase of levels of serum inflammatory biomarkers may indicate the progression of non-motor impairment in PD.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info